Education and Training
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Nivolumab
- other: Placebo
Eligibility
Inclusion Criteria:
- Participants with a first diagnosis of HCC who have undergone a curative resection or
ablation
- Participants are eligible to enroll if they have non-viral related-HCC, or if they
have HBV-HCC, or HCV-HCC
- Child-Pugh Score 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Any evidence of tumor metastasis or co-existing malignant disease
- Participants previously receiving any prior therapy for HCC, including loco-regional
therapies
- Participants who have undergone a liver transplant or those who are in the waiting
list for liver transplantation
- Participants who have received a live/attenuated vaccine within 30 days of
randomization (eg, varicella, zoster, yellow fever, rotavirus, oral polio and measles,
mumps, rubella [MMR]).
Other protocol defined inclusion/exclusion criteria apply
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Flordeliza Mendoza
650-724-2056
Not Recruiting